IR-Med Inc. (OTCQB:IRME)

Developing #point_of_care devices using #infrared & #AI technologies

General Information
Company Name
IR-Med Inc. (OTCQB:IRME)
Founded Year
2012
Location (Offices)
Israel +1
Founders / Decision Makers
Number of Employees
12
Industries
AI, Analytics, Health Care +2
Funding Stage
Grant
Social Media

IR-Med Inc. (OTCQB:IRME) - Company Profile

IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company’s AI process to provide healthcare professionals with decision support in the detection and monitoring of various disease conditions. PressureSafe, the company’s first product based on this platform, is a handheld device designed to revolutionize early detection of pressure injuries (PI) affecting skin and underlying tissue. Pressure Injury in the US alone accounts for $26.8B in healthcare spending and results in 60,000 deaths annually. PressureSafe is expected to contributes to early detection of pressure injuries, regardless of patient skin tone. This will drive equitable healthcare and help reduce the toll and cost of PI. IR-MED holds patents protecting its innovation in noninvasive tissue analysis, and in modeling and analysis of subcutaneous tissue.

Funding Rounds & Investors of IR-Med Inc. (OTCQB:IRME) (0)

View All

There is no investment information

Latest News of IR-Med Inc. (OTCQB:IRME)

View All

No recent news or press coverage available for IR-Med Inc. (OTCQB:IRME) .

Similar Companies to IR-Med Inc. (OTCQB:IRME)

View All
sensawear AG - Similar company to IR-Med Inc. (OTCQB:IRME)
sensawear AG Beyond Pressure
SK Infrared LLC - Similar company to IR-Med Inc. (OTCQB:IRME)
SK Infrared LLC Engineering Infrared Solutions
Biobeat - Similar company to IR-Med Inc. (OTCQB:IRME)
Biobeat AI remote patient monitoring platform, measuring 13 vital signs and triggering early clinical intervention